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Introduction {#sec1.1}
------------

Hematopoietic stem cell transplantation (HSCT) is an important treatment option for a variety of malignant and non-malignant hematological and non-hematological diseases. In autologous transplantation, bone marrow (BM) from a patient is harvested before myeloablation and is then re-infused into the same patient. In contrast, allogeneic transplantation replaces the recipient\'s BM with donor BM after myeloablation. A key feature of HSCT is its reliance on the ability of hematopoietic stem and progenitor cells (HSPCs) to reconstitute the BM and to undergo normal hematopoiesis. Despite the utility of HSCT, a variety of complications can occur, including infection, secondary malignancy, and relapse ([@bib36]). Originally pioneered in children, HSCT is now being used in older patient populations ([@bib62]). However, the incidence of relapse in elderly patients undergoing allogeneic HSCT is 35--40% after 1--2 years, inferring that relapse may be a significant concern ([@bib43]). While the extension of HSCT to older patient populations offers a valuable new treatment option, it is important to understand the risk factors that may influence transplant outcomes in this population.

Donor-derived leukemia (DDL) is a severe complication of HSCT in which patients later develop a secondary leukemia of donor origin ([@bib25]; [@bib89]). Previously considered rare, DDL mayconstitute 5% or more of leukemia relapses, and the number of cases has continued to increase over the last 50 years, particularly since 2000 ([@bib82]; [@bib89]). The median age of recipients with DDL ranges from 31 to 53 years, indicating that it may be more common in adults ([@bib82]; [@bib88]; [@bib89]). DDL is distinguished from traditional relapse as it frequently exhibits different cytogenetic and phenotypic characteristics from the original disease, leading to considerable disease heterogeneity. Acute myeloid leukemia (AML) accounts for about 50% of cases, while acute lymphoid leukemia (ALL) and myelodysplastic syndrome (MDS) represent 23% and 20% of cases, respectively ([@bib82]; [@bib88]; [@bib89]). Notably, while traditional relapses present shortly after HSCT, DDL often exhibits a longer latency with a median time to diagnosis of 26 months, implying that significant changes must occur to promote DDL ([@bib82]; [@bib89]). The heterogeneity of DDL and its origin from donor cells provide diagnostic and treatment challenges, and DDL patients often exhibit poor prognoses ([@bib89]). Mortality has been estimated at 47% within a median follow-up period of 8.5 months, and the median time from diagnosis to death is 10.6 months, underscoring the importance of elucidating the causative factors of DDL and of developing effective therapies ([@bib82]; [@bib88]). While its underlying etiology is not known, contributing factors may include preleukemic donor cells, cytotoxic chemotherapy, bystander radiation damage, defective BM microenvironment, impaired immune surveillance, replicative stress, viral and/or oncogene integration, and occult leukemia in the donor ([@bib89]). Collectively, these studies demonstrate that DDL is a significant adverse event of an important treatment option and that a better understanding of its pathogenesis and risk factors will improve both diagnosis and treatment.

Clonal Hematopoiesis of Indeterminate Potential Represents a Novel Risk Factor for DDL {#sec1.2}
--------------------------------------------------------------------------------------

Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of specific leukocyte clones in healthy individuals ([@bib46]). As individuals age, they accumulate somatic mutations in their HSPCs that give rise to different blood cell lineages, including monocytes, neutrophils, B cells, T cells, and megakaryocytes. These mutations can endow a subpopulation of these cells with a growth advantage ([@bib45]). Using a variant allele frequency (VAF) of 2% or greater in otherwise healthy individuals, the incidence of CHIP may be as high as 95% depending on the method of detection used, demonstrating that it may be quite common ([@bib81]; [@bib95]). The three most commonly mutated genes in CHIP are the epigenetic regulators *Tet2 methycytosine dioxygenase 2* (*TET2*), *DNA methyltransferase* 3A (*DNMT3A*), and *Associated sex combs-like 1* (*ASXL1*) ([@bib46]). Importantly, CHIP is associated with increased risks of hematological malignancy, cardiovascular disease (CVD), and all-cause mortality ([@bib46], [@bib47]). The presence of these preleukemic mutations in donor BM cells may increase the potential for these cells to undergo oncogenic transformation, suggesting that CHIP may be an important risk factor for DDL if transmitted to recipients.

CHIP may contribute to altered transplant outcomes and the development of DDL after both autologous and allogeneic HSCT ([Table 1](#tbl1){ref-type="table"}). Autologous transplantation can facilitate expansion of HSPC clones containing CHIP-associated mutations ([@bib63]). These HSPCs demonstrate long-term engraftment and reconstitute the blood cell lineages. CHIP patients exhibited longer neutrophil reconstitution, longer periods of hospitalization, and prolonged neutropenia. Clones carrying these preleukemic mutations can be detected years before disease onset and expand in response to transplantation ([@bib11]; [@bib63]). The stress of transplantation has been proposed to drive expansion of HSPCs containing CHIP-associated mutations, implicating factors in the transplant environment in the modulation of HSPCs containing CHIP-associated mutations ([@bib63]). In patients who underwent autologous transplantation for lymphoma, CHIP correlated with inferior survival and an increased risk of therapy-related myeloid neoplasms (TMNs) ([@bib32]). Notably, patients carrying more than one mutation at transplantation exhibited an increased risk of TMN. In a similar study, decreased overall survival was specifically observed in patients carrying mutations in DNA repair pathway genes, such as *protein phosphatase*, *Mg*^*2+*^*/Mn*^*2+*^ *dependent 1D* (*PPM1D*), *tumor protein 53* (*TP53*), *BRCA1/BRCA2-containing complex subunit 3* (*BRCC3*), and *RAD21 cohesin complex component* (*RAD21*) ([@bib44]). *PPM1D* can drive clonal hematopoiesis (CH) in response to cytotoxic therapy, inferring a potential role for external stressors in promoting clonal expansion ([@bib42]). However, chemotherapy may not be required, providing the opportunity for multiple contributing factors ([@bib63]). Surprisingly, mutations in other CHIP-associated genes, such as *DNMT3A*, *TET2*, and *ASXL1*, were observed but were not associated with inferior outcomes, implying that specific CHIP-associated mutations may be more susceptible to the autologous transplant environment ([@bib44]). Similarly, in patients undergoing autologous transplantation for multiple myeloma, CHIP correlated with decreased survival and increased multiple myeloma progression, indicating that CHIP can modulate multiple types of hematological malignancy ([@bib61]). Autologous transplantation in CHIP patients is also associated with late non-relapse mortality, demonstrating that CHIP-associated mutations have diverse effects on transplant outcomes ([@bib78]).Table 1Studies Reporting a Role for CHIP in the Outcomes of Both Autologous and Allogeneic HSCTStudyNo. of PatientsDonor/Recipient AgesTransplant TypeDDL CasesClinical Outcomes[@bib35]61 donor/recipient pairs\>60/43 and 26 years (in two DDL cases)allogeneic; DDL cases involved related donors2Focal erythroid dysplasia, myeloid blasts, cytopenias, and MDS were observed in DDL patients.[@bib31], [@bib32]552 donor/recipient pairs40--66/51--68 years in cases with cytopeniasallogeneic; related and unrelated donorsNo cases reported89 patients exhibited cytopenias 6 of which were unexplained.[@bib40]1 donor/recipient pair54/43 yearsallogeneic; related donors1The recipient developed DDL, while the donor later developed AML.[@bib27]500 donor/recipient pairs65/60 yrs (median age)allogeneic; related donors2Increased chronic GVHD and decreased relapse correlated with CHIP. *DNMT3A* mutations associated with a decreased risk of relapse.[@bib32]401 patients170 patients ≥60 years; 231 patients \<60 yearsautologous18 cases of TMNPatients with CHIP exhibited an increased risk of TMN, decreased overall survival, and increased mortality due to CVD.[@bib63]81 patients with solid tumors or lymphoid diseasemean age of 55.4 years at graft collectionautologousNo cases reported; CHIP clones exhibited expansion.Patients with CHIP demonstrated longer neutrophil reconstitution after transplant, longer periods of hospitalization, and prolonged neutropenia.[@bib15]45 donor/recipient pairs37/38 years initially; 57/61 years at study inclusion (median age)allogeneic; related donors1 MDS caseDonor-engrafted clonal hematopoiesis was detected in 5 cases . One case progressed to MDS.[@bib91]25 donor/recipient pairs20--58/19--69 yearsallogeneic; unrelated donorsNo cases reported.Clonal expansion, but not DDL, was observed during the follow-up period.[@bib44]892 lymphoma patients≥18 yearsautologousCHIP correlated with an increased risk of TMN.Patients with mutations in DNA damage repair genes exhibited worse overall survival and increased intensive care admissions.[@bib61]629 multiple myeloma patients58 yearsautologous21 CHIP patients developed MDS or AML after transplant.CHIP patients had worse overall survival and progression-free survival, primarily due to progression of multiple myeloma. CHIP was not associated with an increased risk of TMN.[^1]

In allogeneic transplantation, CHIP also correlates with altered transplant outcomes. Unexplained cytopenias were observed in HSCT recipients of CHIP donors, demonstrating that donor clones containing CHIP-associated mutations can be transmitted to transplant recipients and can influence recipient blood cell populations ([@bib31] ). CH is commonly detected in both donors and recipients, and these transmitted clones can expand in recipients ([@bib15]; [@bib91]). The presence of unexplained cytopenias is more common in recipients with older donors, consistent with a possible role for CHIP in pathogenesis ([@bib31]). While cytopenias are observed in DDL cases, it is not known if they contribute to DDL pathogenesis ([@bib88]). HSPCs from older CHIP donors can also increase the risk of chronic graft-versus-host disease (cGVHD), a multi-system inflammatory response that occurs about 100 days after transplant ([@bib27]; [@bib57]). The longer latency of cGVHD is consistent with the later presentation of DDL, compared with traditional relapse. Surprisingly, CHIP-associated mutations of donor origin also correlate with a reduced occurrence of relapse ([@bib27]). It was postulated that, due to their enhanced growth advantage, HSPCs bearing CHIP-associated mutations outcompete the residual leukemic HSPCs that can cause traditional relapse. Indeed, cGVHD may be inversely related to the occurrence of primary disease relapse; however, it may also create an immunosuppressive environment in which leukemia and other cancers can arise ([@bib67]; [@bib69]).

Similarly, MDS, a clonal disorder characterized by BM failure that frequently progresses to AML, may be an early or intermediary phase in progression to DDL, suggesting that DDL may present along a spectrum of disease progression ([@bib79]; [@bib82]; [@bib89]). MDS has been observed in up to 70% of DDL cases, and CHIP-associated MDS after allogeneic transplantation has been reported ([@bib15]; [@bib74]; [@bib88]). Loss of *Asxl1* in mice causes an MDS-like phenotype, and somatic mutations are associated with inferior outcomes in MDS patients undergoing HSCT, implicating CHIP-associated mutations in MDS ([@bib1]; [@bib9]). Germline mutations, including those in *GATA binding protein 2* (*GATA2*), *DEAD-box helicase 41* (*DDX41*), *CCAAT enhancer binding protein alpha* (*CEBPA*), and *runt-related transcription factor 1* (*RUNX1*), can also cause donor-derived AML and MDS; however, the implications of CHIP in patients with these germline mutations has not yet been explored ([@bib10]; [@bib29]; [@bib64]; [@bib93]). In particular, DDX41 mutations have been observed in older DDL patients together with mutations in CHIP-associated genes, providing an opportunity for interactions between germline mutations and CHIP-associated mutations in DDL ([@bib10]).

As clonal evolution and the acquisition of mutations contribute to leukemogenesis, additional events may be required to drive CHIP-mutant HSPCs toward DDL ([@bib52]; [@bib71]; [@bib72]). Patients with CHIP-associated DDL exhibit multiple mutations in blood cell lineages and complex clonal compositions ([@bib15]; [@bib35]; [@bib40]; [@bib83]). The combinations of clones that arise and the specific mutations that they carry may influence their leukemic potential ([@bib90]). The presence of additional mutations in clones originally containing CHIP-associated mutations and the evolution of independent clones with new mutations have been detected, highlighting the complexity of clonal evolution ([@bib15]). The combination of loss of *Tet2* with constitutive activation of the *fms related tyrosine kinase* (*Flt3*) alters the chronic myelomonoctyic leukemia- or myeloproliferative neoplasm-like phenotype characteristic of single mutations to an AML-like phenotype ([@bib68]; [@bib75]). This finding demonstrates that additional mutations can modify the disease presentation and may help explain the heterogeneity observed in DDL. The presence of both germline and somatic mutations may further enhance clonal complexity in the context of DDL. The clonal evolution of mutant HSPCs is also consistent with the longer latency observed in DDL compared with traditional relapse, indicating that time is needed to acquire these mutations. Consistent with the observation that clones carrying CHIP-associated mutations may persist for years before progressing to DDL, somatic mutations can be present years before the diagnosis of AML ([@bib20]). Notably, in many of these studies, donor mutations in *DNMT3A* are frequently transmitted to recipients and contribute to cGVHD, clonal evolution, and DDL, supporting a unique role for *DNMT3A* ([@bib15]; [@bib27]; [@bib31]; [@bib35]; [@bib40]; [@bib94]). CHIP-associated mutations in different genes may have differential propensities to affect HSCT and promote DDL; however, additional studies are needed. Collectively, these studies suggest that CHIP-associated mutations of donor origin can alter HSCT outcomes and may provide the context in which DDL can develop. The ability of HSPCs carrying CHIP-associated mutations to impair graft function indicates a need for further studies to evaluate the incidence of CHIP in transplant failure. cGVHD and MDS may be intermediary stages in the development of DDL that can progress through clonal evolution and may differ from their traditional presentations in the context of CHIP ([Figure 1](#fig1){ref-type="fig"}). However, it is not known if CHIP-associated cGVHD or MDS can progress to DDL and, if so, which factors promote this transition.Figure 1cGVHD and MDS May Represent Intermediary Stages in the Development of DDLBoth HSPCs containing CHIP-associated mutations and the aging, conditioned, and leukemic BM microenvironment can cause inflammation through the secretion of cytokines and may lead to cGVHD or MDS. These inflammatory states may facilitate expansion of CHIP clones, acquisition of new mutations, or changes in hematopoiesis that promote DDL. Additional triggers (lightning bolt), such as comorbidities, may also be needed to progress to DDL. EC, endothelial cells; MC, mesenchymal cells.

Both Cell-autonomous and Non-cell-autonomous Factors May Contribute to DDL {#sec1.3}
--------------------------------------------------------------------------

The "seed and soil" hypothesis is an important concept in DDL and may be relevant in considering the role of CHIP in DDL ([@bib26]). It highlights the potential contributions of both intrinsic and extrinsic factors to leukemogenesis. One hypothesis regarding DDL pathogenesis is that HSPCs acquire preleukemic mutations due to the stresses of the transplantation environment ([@bib26]; [@bib89]). However, in CHIP, HSPCs already carry preleukemic mutations and may be primed to promote DDL. The ability of clones containing CHIP-associated mutations to expand within the HSPC population supports an inherent growth advantage for these mutations. Cell-autonomous properties of HSPCs bearing CHIP-associated mutations may depend on the epigenetic state of these cells and may be retained under stressful conditions, including transplantation, inflammation, and genotoxic stress, implicating intrinsic features of HSPCs in clonal behavior during DDL ([@bib96]). The presence of germline mutations in donor HSPCs may also endow these cells with cell-autonomous advantages.

CHIP-associated mutations in different epigenetic regulators can bias the differentiation potential of HSPCs, leading to different clinical presentations ([@bib92]). Similarly, inactivation of *Tet2* and *Asxl1* in mice results in myeloid pathologies, whereas loss of *Dnmt3a* causes both lymphoid and myeloid disease patterns ([@bib1]; [@bib55]; [@bib58]). Consequently, these mutations may influence the presentation of DDL. In a cohort of CHIP patients, higher VAFs were detected in granulocytes, monocytes, and natural killer cells, compared with B and T cells, indicating a propensity for CHIP-associated mutations in myeloid lineages ([@bib3]). However, in DDL patients, CHIP-associated mutations are detected in both myeloid and lymphoid lineages, supporting the presence of these mutations in HSPCs ([@bib15]; [@bib40]). Intriguingly, in a 7-year longitudinal study of a single patient, only the myeloid lineage acquired additional mutations and progressed to leukemia ([@bib40]). Consistently, most DDL cases cause AML; however, as DDL also includes lymphoid leukemias, a distinct mechanism may exist for the development of donor-derived lymphoid leukemias ([@bib82]; [@bib89]). It is not yet known if CHIP contributes to both myeloid and lymphoid presentations of DDL. Germline mutations, such as those in *RUNX1*, are associated with myeloid malignancies, and may, therefore, further bias HSPCs toward myeloid lineages in DDL ([@bib64]). As CHIP-associated mutations are typically observed in older individuals, intrinsic factors of aged HSPCs may also contribute to skewing of differentiation toward myeloid lineages ([@bib59]). In addition to influencing expansion and differentiation, CHIP-associated mutations can influence signaling in HSPCs and their progeny. For example, loss of *Tet2* and *Dnmt3a* in mice promotes inflammation ([@bib16]; [@bib18]; [@bib54]; [@bib98]). The release of cytokines by *Tet2*-deficient HSPCs alters the frequencies of mesenchymal stem cells, endothelial cells, and osteoblasts and may make the BM microenvironment more conducive to DDL ([@bib56]; [@bib68]) ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Together, these studies demonstrate that HSPCs bearing CHIP-associated mutations may intrinsically contribute to DDL pathogenesis via multiple mechanisms.Figure 2Models for the CellAutonomous and Non-cell-autonomous Factors that May Promote CHIP-Associated DDL(A) In a cell-autonomous context, HSPCs carrying CHIP-associated mutations may release cytokines that can remodel the BM microenvironment to promote the development of DDL by altering normal hematopoiesis, by facilitating the expansion of CHIP clones, and/or by driving the acquisition of new mutations.(B) In a non-cell-autonomous scenario, the aged, conditioned, or leukemic BM microenvironment of the recipient can secrete cytokines to promote the expansion of donor HSPCs containing CHIP-associated mutations, the acquisition of new mutations, and/or the disruption of normal hematopoiesis, which may lead to DDL. EC, endothelial cells; MC, mesenchymal cells.

While preleukemic mutations can provide donor HSPCs with cell-autonomous advantages and signaling mechanisms, the BM microenvironment promotes leukemogenesis via non-cell-autonomous mechanisms that may also be relevant in DDL ([@bib73]). Consisting of diverse cell populations, including osteoblasts, mesenchymal cells, and endothelial cells, the BM microenvironment provides signaling and secreted factors that facilitate the engraftment of donor HSPCs ([@bib59]). However, conditioning regimens can radically alter the BM microenvironment, damaging the stromal cells and impairing their ability to support hematopoiesis during recovery ([@bib7]; [@bib22]). Significant changes in the gene expression and DNA methylation of multipotent mesenchymal stromal cells and HSPCs are detected in recipient BM up to 1 year after transplant ([@bib76]; [@bib86]). The potential role for methylation in the transplant BM microenvironment is particularly compelling considering that *DNMT3A* mutations are frequently present in CHIP-associated DDL.

Inflammation is also an important regulator of the BM microenvironment during transplantation ([@bib77]). Interleukin-1β (IL-1β) is secreted by stromal cells in response to irradiation and can modulate both mesenchymal cell proliferation and hematopoiesis ([@bib12], [@bib13]). Importantly, its ability to regulate hematopoiesis may be context-dependent ([@bib19]). Transplantation stresses may create an environment that selects for HSPCs bearing CHIP-associated mutations from the transplanted BM. Consistent with this notion, inflammation facilitates the expansion of *Tet2*-deficient HSPCs ([@bib2]; [@bib16]). In addition to conditioning, the BM microenvironment in transplant patients has been exposed to hematological malignancy and, therefore, may already be altered. For example, AML can remodel the BM microenvironment to support leukemic cells and suppress normal hematopoiesis ([@bib8]; [@bib50]). The extent of this remodeling may affect the likelihood of transplanted HSPCs bearing CHIP-associated mutations to progress to DDL. Compared with primary hematological malignancies associated with CHIP the transplantation environment and previous exposure to hematological malignancy are unique stresses to HSPCs carrying CHIP-associated mutations in DDL and may shape the potential of the BM microenvironment and donor HSPCs to promote DDL.

Age alters the BM microenvironment and may affect the efficiency of HSCT in elderly patients ([@bib41]; [@bib87]). Together with metabolic and epigenetic shifts, the composition of supporting cells and the levels of secreted factors in the BM microenvironment change with age ([@bib59]; [@bib87]). Detected both systemically and in the BM stroma, inflammation is an important event during aging and can alter hematopoiesis ([@bib49]; [@bib38]). As inflammation can contribute to cancer pathogenesis, one possible explanation for the development of DDL from CHIP donors is that hematopoietic lineages exhibiting pro-inflammatory phenotypes may modify the BM microenvironment and hematopoiesis to promote leukemogenesis ([Figure 2](#fig2){ref-type="fig"}) ([@bib39]; [@bib53]). For example, chronic exposure to IL-1 reduces HSPC self-renewal capacity, skews differentiation toward myeloid lineages, hinders transplantation, and contributes to hematological malignancy ([@bib66]; [@bib6]). As cytokines regulate hematopoiesis, the perturbation of cytokine signaling associated with CHIP-associated HSPCs, transplantation, and aging may alter the hematopoietic potential of the transplanted donor cells ([Figure 2](#fig2){ref-type="fig"}) ([@bib60]). Leukemic HSPCs exhibit higher self-renewal capacity when transplanted in adult mice, compared with neonates, suggesting that the aged BM microenvironment more effectively promotes leukemogenesis ([@bib51]). It is unclear if the clinical presentation and pathogenesis of DDL differ with age and the mechanisms by which HSPCs bearing CHIP-associated mutations interact with the BM microenvironments of different ages are not known ([@bib88], [@bib89]). Recently, CHIP-associated mutations were detected in much younger individuals ([@bib91]). With these younger individuals as donors, efficient engraftment and expansion of clones bearing CHIP-associated mutations were reported, but DDL or GVHD were not observed up to 100 days after transplant. A longer latency, additional environmental factors, or aged HSPCs may be needed to drive progression to DDL or GVHD. The impact of and the mechanisms by which the combined stresses of aging and transplantation affect the BM microenvironment are not yet known. Transplantation and HSPCs carrying CHIP-associated mutations may further exacerbate and prolong age-associated inflammation, and this process may support DDL pathogenesis ([@bib49]).

Inflammation in the BM microenvironment can also cause DNA damage, which may drive the acquisition of additional mutations that can promote DDL ([@bib89]; [@bib53]). Inflammation in BM stromal cells exacerbates genotoxic stress and promotes progression of preleukemic conditions ([@bib97]). HSPCs carrying CHIP-associated mutations may be more susceptible to the acquisition of new mutations, facilitating the clonal evolution needed to progress to DDL ([@bib65]). Seventy-two percent of DDL cases exhibit abnormal karyotypes, and CHIP donors and their recipients have shorter telomeres, supporting a role for genotoxic stress in CHIP-associated DDL ([@bib15]; [@bib82]). As inflammation contributes to both cGVHD and MDS, these inflammatory states may provide the necessary stresses to drive the acquisition of additional mutations and transformation to DDL ([Figure 1](#fig1){ref-type="fig"}) ([@bib57]; [@bib70]). The aging BM microenvironment also exhibits increased levels of reactive oxygen species, which can cause genotoxic stress in HSPCs ([@bib87]). Furthermore, in cases of CHIP-associated TMN, mutations in *TP53* and *PPM1D*, key regulators in DNA damage repair, are prominent and can cause clonal expansion ([@bib17]; [@bib32]). As germline mutations are associated with MDS and AML, the presence of these mutations in the recipient BM microenvironment may also create an environment conducive to DDL ([@bib48]).

Likely, a combination of cell-autonomous and non-cell-autonomous factors is involved in DDL pathogenesis, and additional studies are needed to elucidate the importance of these factors in disease progression ([Figure 2](#fig2){ref-type="fig"}). Inflammatory signals may originate from HSPCs bearing CHIP-associated mutations, from the aged transplant BM microenvironment, or both, and significant communication may occur between the CHIP-mutant HSPCs and the BM microenvironment. These inflammatory signals may lead to cGVHD, MDS, and/or DDL. Our group recently showed that preleukemic *Tet2*-deficient HSPCs can modulate the BM microenvironment via pro-inflammatory factors and that these cells cause myeloproliferative neoplasms when transplanted into a leukemic environment ([@bib68]). These findings demonstrate that the HSPCs carrying CHIP-associated mutations and the BM microenvironment may act in concert to drive DDL.

In further support of the role of the BM microenvironment, not all predisposed individuals develop CHIP-associated malignancy ([@bib15]; [@bib35]; [@bib89]). For example, a recipient can develop DDL, while the donor does not exhibit hematological malignancy, inferring that the recipients\' BM microenvironment may stimulate HSPCs with CHIP-associated mutations to promote DDL. Alternatively, the donor and the recipient can present with different hematological malignancies and clinical outcomes. In 73 donor-recipient pairs in which the recipients developed DDL, 85% of the donors remained healthy, while 12% and 3% exhibited hematological malignancies and non-hematologic cancers, respectively ([@bib82]). Consistent with the relatively low risk of developing CHIP-associated hematological malignancies, this study indicates that most donors do not develop cancer ([@bib80]). However, two distinct leukemias with different clinical outcomes arose in a related donor-recipient pair followed over time ([@bib40]). This case shows that despite the presence of common initial mutations, additional factors unique to each patient may modulate the evolution and presentation of leukemia.

As CHIP is modulated by comorbidities, other conditions may influence DDL and may account for differences in clinical presentation between donors and recipients ([@bib24]; [@bib99]). In addition, different hematopoietic stressors may exert distinct effects on the expansion of clones carrying specific CHIP-associated mutations ([@bib90]). The wide variety of potential stresses present in elderly patient populations may be responsible for the significant heterogeneity observed in DDL patients ([Figure 3](#fig3){ref-type="fig"}). Inferior outcomes have been observed in elderly patients with comorbidities that undergo HSCT; however, it is not known if DDL and CHIP are more common in these patients ([@bib37]; [@bib62]). These triggers imply that the causative factors of DDL may be more diverse than previously thought and that DDL should be considered in broader contexts clinically.Figure 3HSPCs Carrying CHIP-Associated Mutations Can Lead to Different Outcomes in Donors and RecipientsIn both scenarios, mutant HSPCs can either maintain the size of the mutant clones (red) or these clones can expand. In donors, the expansion of CHIP clones can lead either to CVD or the acquisition of additional mutations (green). In recipients, the expansion of CHIP clones can lead to the acquisition of additional mutations, MDS, cGVHD, or the development of CVD. The acquisition of additional mutations likely requires a stressful event (lightning bolt) to drive mutagenesis. It is unclear whether CHIP-associated MDS and cGVHD can progress to DDL and whether additional mutations are needed.

The Role of CHIP in DDL May Expand the Clinical Scope of DDL to Include Solid Organ Transplants, Non-hematologic Cancers, and CVD {#sec1.4}
---------------------------------------------------------------------------------------------------------------------------------

As new causative and modulatory factors for DDL are being discovered, it may present in a variety of ways clinically. In addition to HSCT, DDL has been reported in cases of solid organ transplants ([@bib14]; [@bib34]; [@bib84]). A 57-year-old woman developed acute promyelocytic leukemia 2 years after receiving a liver transplant from a 16-year-old boy ([@bib14]). AML was observed in a 43-year-old man 3 years after a liver transplant and in a 69-year-old kidney transplant recipient 2 years post-transplant ([@bib34]; [@bib84]). Notably, in the latter case, the donor was an 81-year-old woman with an unremarkable medical history. As in DDL due to HSCT, these cases exhibited long latencies to the development of leukemia, but it is not known if CHIP contributes to these manifestations of DDL. Significantly, the patients in these cases succumbed to their diseases, indicating that DDL from solid organ transplants is also severe ([@bib14]; [@bib34]; [@bib84]). The manifestation of DDL in these cases is particularly remarkable because the organs transplanted were not typically hematologic organs in adults, suggesting that other mechanisms may be involved in DDL. While the possible contribution of CHIP to DDL in solid organ transplants has not yet been investigated, the occurrence of DDL from solid organ transplants raises concerns about screening for CHIP in solid organ donors in addition to HSCT.

The identification of TMNs in CHIP patients undergoing autologous transplantation for lymphoma indicates that HSPCs containing CHIP-associated mutations may be particularly susceptible to cancer treatments and other environmental stresses ([@bib32]; [@bib44]). However, CHIP is also commonly detected in cancer patients before treatment and can predispose patients with non-hematologic cancers to the development of TMNs ([@bib3]; [@bib33]; [@bib85]). Patients with solid cancers undergoing treatment exhibited VAF changes of at least 50%, further supporting the sensitivity of hematopoietic cells bearing CHIP-associated mutations to external stresses ([@bib3]). In addition, depending on the gene mutated, some patients needed more frequent blood cell transfusions and dose reductions, identifying a role for CHIP in guiding the treatment of non-hematologic cancers. These studies suggest that elderly cancer patients receiving treatment may be at an increased risk of developing DDL or other CHIP-associated conditions, especially if they have other comorbidities. Additional studies are needed to better understand these potential risk factors. These studies support a more expansive evaluation of CHIP in cancer patients generally.

While the risk of developing hematologic malignancies from CHIP is 0.5%--1%, there is a much greater risk of developing CVD ([@bib23]; [@bib47]; [@bib80]). Notably, CVD is also a significant morbidity in HSCT patients ([@bib4]). As in CHIP, HSCT patients exhibit heart failure and coronary artery disease; however, the mechanisms underlying this presentation are not known ([@bib5]). In a model of *Tet2* deficiency in atherosclerosis-prone *low-density lipoprotein receptor*-deficient mice, macrophages secreting IL-1β exacerbate atherosclerosis ([@bib28]). An increased risk of mortality due to CVD was observed in CHIP patients undergoing autologous transplantation for lymphoma, inferring a possible role for CHIP in transplant-associated CVD ([@bib4]). Importantly, it is not known if CHIP increases the risk of CVD in DDL patients and if the presence of CHIP in an HSCT donor or recipient directly contributes to CVD. However, fewer CHIP-mutant cells may be required to promote CVD than hematological malignancy, highlighting the importance of evaluating CVD in HSCT patients and in patients with CHIP-associated DDL. Additional studies are needed to investigate these possibilities. Nonetheless, these studies infer a potential link between the hematopoietic and cardiovascular systems that may have significant implications for pathogenesis and the treatment of HSCT and DDL patients.

Collectively, these different clinical manifestations of DDL underscore a need to broaden the clinical approach to these patients both in diagnosis and treatment. A better understanding of the potentially diverse clinical presentations of these patients will facilitate their identification and proper diagnosis at earlier stages and promote the development of novel therapeutics.

CHIP Has Significant Implications for DDL {#sec1.5}
-----------------------------------------

The potential of CHIP to contribute to DDL may also be a concern with other cell-based products, such as chimeric antigen receptor T cells and donor lymphocyte infusions (DLIs); however, more information is needed. With DLIs, the composition of both donor and recipient HSPC clones may evolve over time and respond to different stimuli, altering the factors influencing DDL pathogenesis. CHIP-associated inflammation may also have clinical implications. Our group has shown that inhibition of inflammation using the small-molecule APX3330 blocks clonal expansion of *Tet2*-deficient HSPCs ([@bib16]). However, it is also important to understand the effects of anti-inflammatory agents on the BM microenvironment as both HSPCs and the BM microenvironment may be sources of inflammatory signals in CHIP-associated DDL.

Currently, screening of donors for CHIP is controversial ([@bib21]; [@bib30]). Screening for donors with CHIP before transplantation may prevent adverse effects in HSCT patients as seemingly healthy individuals may harbor growth-promoting mutations in their HSPCs. However, challenges exist in the ability to effectively screen for all possible CHIP-associated mutations. As improved technologies facilitate the detection of CHIP at lower VAFs, the elucidation of a pathogenic threshold and its clinical significance are complex. The biological context of these mutations in the recipient and the influences of comorbidities may govern their behavior and clinical relevance. Screening for germline mutations is recommended to avoid related donors in these cases ([@bib29]; [@bib48]). While the consequences of germline mutations for CHIP-associated DDL are not yet known, future studies are needed to understand the implications of these mutations and cancer predisposition syndromes, such as neurofibromatosis, Bloom syndrome, Fanconi anemia, and Li-Fraumeni syndrome, for CHIP-associated DDL ([@bib89]). In addition, the status of CH in the donor can evolve over time, supporting long-term follow-up of both donors and recipients. It also is not known if there are CHIP-independent mechanisms of DDL and if there are differences in clinical presentation, mutations, and prognosis in patients with CHIP-associated DDL, compared with DDL that is independent of CHIP. Ultimately, further studies are needed to understand the effectiveness of donor screening.

Conclusions {#sec1.6}
-----------

CHIP is a relatively common novel condition in elderly individuals and may be an important risk factor for the development of DDL, a significant complication of HSCT. The more frequent use of HSCT in older populations is particularly concerning as CHIP-associated mutations are frequently observed in individuals older than 65 years and increase with age. Recent studies suggest that CHIP may adversely affect transplant outcomes and promote DDL; however, many unanswered questions remain. CHIP may contribute to DDL pathogenesis via cell-autonomous and non-cell-autonomous mechanisms and may lead to novel presentations of donor-derived disease, such as CVD. A better understanding of the contributions of CHIP to DDL will provide important knowledge about the mechanisms of leukemogenesis and will have significant implications for the diagnosis, treatment, and the development of novel therapies for DDL.
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